HAR-171

CAS No. 1349902-37-9

HAR-171( HAR171 )

Catalog No. M11415 CAS No. 1349902-37-9

HAR-171 is a small molecule gp120-CD40 blocker that acts as a highly potent HIV entry inhibitor with IC50 of 0.43 uM against YTA48P virus.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    HAR-171
  • Note
    Research use only, not for human use.
  • Brief Description
    HAR-171 is a small molecule gp120-CD40 blocker that acts as a highly potent HIV entry inhibitor with IC50 of 0.43 uM against YTA48P virus.
  • Description
    HAR-171 is a small molecule gp120-CD40 blocker that acts as a highly potent HIV entry inhibitor with IC50 of 0.43 uM against YTA48P virus with no significant cytotoxicity (CC50>120 uM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    HAR171
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1349902-37-9
  • Formula Weight
    417.978
  • Molecular Formula
    C23H32ClN3O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    N1-(4-chlorophenyl)-N2-(7-azadispiro[5.1.58.36]hexadecan-15-yl)oxalamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Narumi T, et al. Bioorg Med Chem. 2013 May 1;21(9):2518-26. 2. Ohashi N, et al. ChemMedChem. 2016 Apr 19;11(8):940-6.
molnova catalog
related products
  • DDX3-IN-16d

    A small molecule inhibitor (IC50=0.3 uM) of DEAD-box polypeptide 3 (DDX3).

  • Amprenavir

    A potent HIV-1 protease inhibitor with IC50 of 80 nM, has mean IC50 of 12 nM against 6 HIV clinical isolates.

  • HIV p17 Gag 77-85

    HIV p17 Gag (77-85) is an attractive target for molecular intervention, because it is involved in the viral replication cycle at both the pre- and postintegration levels. In the present experiments, we targeted p17 by intracellularly expressing a cDNA encoding an Ab to p17.